secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2024-10-23T23:59:59+00:00
Accession:  0001558370-24-013518
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corvus Pharmaceuticals enters sub-sublease for 20,916 sq ft in South San Francisco
--------------------------------------------------------------------------------

- Sublease term of 36 months from later of consent or Feb 1, 2025; option to extend up to May 2030.
- Monthly base rent ranges $33,833 to $47,200 over lease term; prepaid rent of $231,235 applied to first three months.
- Security deposit of $75,000 required; triple net lease with Subtenant paying proportionate share of expenses.
- Premises at 901 Gateway Boulevard, South San Francisco, comprising third floor and first floor space.
- Sublease is from NewLimit under existing prime sublease from Theravance Biopharma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000155837024013518/0001558370-24-013518-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000155837024013518/crvs-20241022x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-013518

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer